Rheumatoid arthritis: from palliation to remission in two decades

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 14, Issue 6, 2014, Pages s50-s55

  Brown, Philip M ^a   Isaacs, John D ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

biologics; biomarkers; immune tolerance; Rheumatoid arthritis; stratified medicine

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER;

ARTHRITIS, RHEUMATOID; HUMAN; IMMUNOLOGY; PALLIATIVE THERAPY; PATHOPHYSIOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; HUMANS; PALLIATIVE CARE;

EID: 84973413743     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.14-6-s50     Document Type: Article

References (32)

1. Strand, V, Kimberly, R, Isaacs, JD, Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 6 (2007), 75–92 10.1038/nrd2196.
2. Kirwan, JR, Conceptual issues in scoring radiographic progression in rheumatoid arthritis. J Rheumatol 26 (1999), 720–725.
3. Young, A, Koduri, G, Batley, M, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology 46 (2007), 350–357 10.1093/rheumatology/kel253.
4. van der Linden, MP, le Cessie, S, Raza, K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheumatol 62 (2010), 3537–3546 10.1002/art.27692.
5. Grigor, C, Capell, H, Stirling, A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (2004), 263–269 10.1016/S0140-6736(04)16676-2.
6. Smolen, JS, Landewe, R, Breedveld, FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73 (2014), 492–509 10.1136/annrheumdis-2013-204573.
7. Feldmann, M, Maini, RN, Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Ann Rev Immunol 19 (2001), 163–196 10.1146/annurev.immunol.19.1.163.
8. Weinblatt, ME, Kremer, JM, Bankhurst, AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 (1999), 253–259 10.1056/NEJM199901283400401.
9. Lipsky, PE, van der Heijde, DM, St Clair, EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 (2000), 1594–1602 10.1056/NEJM200011303432202.
10. Keystone, EC, Kavanaugh, AF, Sharp, JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheumatol 50 (2004), 1400–1411 10.1002/art.20217.
11. Verstappen, SM, Outcomes of early rheumatoid arthritis – the WHO ICF framework. Best Prac Res Clin Rheumatol 27 (2013), 555–570 10.1016/j.berh.2013.09.004.
12. Nikiphorou, E, Carpenter, L, Morris, S, et al. Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts. Arth Rheumatol 66 (2014), 1081–1089 10.1002/art.38344.
13. Jamsen, E, Virta, LJ, Hakala, M, Kauppi, MJ, Malmivaara, A, Lehto, MU, The decline in joint replacement surgery in rheumatoid arthritis is associated with a concomitant increase in the intensity of anti-rheumatic therapy: a nationwide register-based study from 1995 through 2010. Acta Orthopaedica 84 (2013), 331–337 10.3109/17453674.2013.810519.
14. Thalayasingam, N, Isaacs, JD, Anti-TNF therapy. Best Prac Res Clin Rheumatol 25 (2011), 549–567 10.1016/j.berh.2011.10.004.
15. Galloway, JB, Hyrich, KL, Mercer, LK, et al. Anti-TNF therapy is -associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50 (2011), 124–131 10.1093/rheumatology/keq242.
16. Keane, J, Gershon, S, Wise, RP, et al. Tuberculosis associated with -infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001), 1098–1104 10.1056/NEJMoa011110.
17. Mariette, X, Matucci-Cerinic, M, Pavelka, K, et al. Malignancies -associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and -meta-analysis. Ann Rheum Dis 70 (2011), 1895–1904 10.1136/ard.2010.149419.
18. Cohen, SB, Emery, P, Greenwald, MW, et al. Rituximab for -rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, -placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheumatol 54 (2006), 2793–2806 10.1002/art.22025.
19. van Vollenhoven, RF, Emery, P, Bingham, CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72 (2013), 1496–1502 10.1136/annrheumdis-2012-201956.
20. Molloy, ES, Calabrese, LH, Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheumatol 64 (2012), 3043–3051 10.1002/art.34468.
21. Emery, P, Fleischmann, R, Filipowicz-Sosnowska, A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheumatol 54 (2006), 1390–1400 10.1002/art.21778.
22. Genovese, MC, Becker, JC, Schiff, M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353 (2005), 1114–1123 10.1056/NEJMoa050524.
23. Kremer, JM, Genant, HK, Moreland, LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Internal Med 144 (2006), 865–876 10.7326/0003-4819-144-12-200606200-00003.
24. Schiff, M, Abatacept treatment for rheumatoid arthritis. Rheumatology 50 (2011), 437–449 10.1093/rheumatology/keq287.
25. Alten, R, Kaine, J, Keystone, E, Nash, P, Delaet, I, Genovese, MC, -Long-term safety of subcutaneous abatacept in rheumatoid arthritis: Integrated analysis of clinical trial data of up to 4.75 years of treatment. Arthritis Rheumatol 66 (2014), 1987–1997 10.1002/art.38687.
26. Weinblatt, ME, Moreland, LW, Westhovens, R, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol 40 (2013), 787–797 10.3899/jrheum.120906.
27. Emery, P, Keystone, E, Tony, HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67 (2008), 1516–1523 10.1136/ard.2008.092932.
28. Smolen, JS, Beaulieu, A, Rubbert-Roth, A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, -randomised trial. Lancet 371 (2008), 987–997 10.1016/S0140-6736(08)60453-5.
29. 29 Smolen JS, Ramos-Remus CR, Mysler EF, Day B, Wiese C, Alten R,. Tocilizumab improves hemoglobin levels and FACIT-Fatigue scores in patients with rheumatoid arthritis - Poster Presentation. Ann Rheum Dis.
30. Schiff, MH, Kremer, JM, Jahreis, A, Vernon, E, Isaacs, JD, van Vollenhoven, RF, Integrated safety in tocilizumab clinical trials. Arthritis Res Ther, 13, 2011, R 10.1186/ar3455.
31. Isaacs, JD, The changing face of rheumatoid arthritis: sustained remission for all?. Nat Rev Immunol 10 (2010), 605–611 10.1038/nri2804.
32. Nielen, MM, van Schaardenburg, D, Reesink, HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheumatol 50 (2004), 380–386 10.1002/art.20018.